Dupixent (dupilumab) is a medication used to treat various inflammatory and allergic conditions such as atopic dermatitis, asthma, and rhinitis. It is a biologic medication developed by Sanofi and Regeneron Pharmaceuticals.

As of my knowledge cutoff in December 2023, Dupixent is not yet available as a generic medication. [1] According to the FDA's Orange Book, there is no approved generic equivalent of Dupixent. [2]

However, it's essential to note that biologic medications like Dupixent often have a complex development process and may take several years to approve a generic version. Additionally, patent laws and extensions may impact the availability of a generic version. [3]

DrugPatentWatch.com provides information on patent expiration dates for medications, including Dupixent. However, at this time, the patent for Dupixent is still in effect, which could delay the availability of a generic version. [4] For more information on patent expiration dates, you can visit DrugPatentWatch.com. [5]

It's also worth noting that even without an FDA-approved generic version, some pharmacies or online retailers might offer generic or biosimilar versions of Dupixent. These products may be approved in other countries or through the FDA's 505(b)(2) pathway, which allows for a generic version to be developed based on the safety and efficacy data from the original medication. However, the quality and efficacy of these products can vary, and patients should consult with their healthcare provider before switching to a non-FDA-approved generic or biosimilar version.

Sources:

[1] https://www.drugs.com/dupixent.html
[2] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=tab_view.table
[3] https://www.pharma.com/insights/when-will-biologics-be-generics
[4] https://www.drugpatentwatch.com/dupixent/
[5] https://www.drugpatentwatch.com/